Ozempic Associated with Decreased Risk of Dementia Among Other Outcomes
Findings from a University of Oxford study published in the Lancet demonstrated Ozempic decreased the risk of developing dementia by 48% vs. sitagliptin after one year and protected against other cognitive problems (view article; view study). For context, the study evaluated 12-month neurological and psychiatric outcomes of semaglutide vs. sitagliptin, empagliflozin, and glipizide using electronic health records. Below, FENIX provides highlights and insights into the study’s findings.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.